Patients with persistent upper-back itch from notalgia paresthetica may get some relief with oral difelikefalin (Korsuva), phase 2 data from a randomized, double-blinded placebo-controlled trial ...

A selective kappa opioid receptor agonist in patients with notalgia paresthetica led to "modestly" greater improvements in itchiness over placebo, but was associated with adverse events, a randomized ...

New York, NY (February 8, 2023) – Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no ...

STAMFORD, Conn., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to ...

STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia ...

STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...

Notalgia paresthetica, a neuropathic disorder characterized by recurrent itching in the upper back, is resistant to many treatments. Oral difelikefalin is being studied as a potential therapy. New ...

Notalgia paresthetica is an unexplored neuropathy, and yet NP is relatively common. The disease is a chronic neuropathic pruritic condition characterized by pruritus of the upper back, often leading ...